NCNA

Nucana

0.04

0.00-8.86%

After Hours: 0.0396 +0.0005 +1.28%19:59 08/01 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.0425/0.0429

TODAY RANGE0.0353-0.0425

VOL124.58M

MARKET CAP14.92M

52 WEEK RANGE0.0325-10.79

AVG VOL (3M)245.94M

% TURNOVER32.64%

TURNOVER--

P/E (TTM)-0.0055

% RANGE16.78%

EPS(TTM)-7.0864

P/E(FORWARD)-0.7519

P/B0.0441

BVPS0.8867

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP14.92M

SHARES OUTSTANDING381.64M

NEXT EARNINGS08/13-08/18

FREE FLOAT381.62M

LOT SIZE1

EX-DATE08/08/2025

News

Press Releases

Financial Reports

Profile

TipRanks·21h ago
NuCana Announces ADS Ratio Change Effective August 11, 2025
TipRanks·22h ago
NuCana announces ADS ratio change
Reuters·22h ago
NUCANA PLC - ADS RATIO CHANGE EFFECTIVE AUGUST 11, 2025
TipRanks·07/21 12:47
NuCana Cancels Series A Warrants Post-ATM Execution
TipRanks·07/21 12:28
NuCana cancels all outstanding Series A Warrants
Benzinga·07/21 12:07
NuCana Cancels All Remaining Series A Warrants After Raising Required Capital, Eliminating Overhang From May 2025 Offering
TipRanks·07/11 15:17
NuCana Announces ADS Ratio Change to Enhance Liquidity
Benzinga·07/11 14:35
NuCana Announces 1-For-200 ADS Ratio Change, Effective August 8, 2025
Reuters·07/11 14:32
BRIEF-NuCana To Implement ADS Ratio Change Of 1 ADS to 5,000 Ordinary Shares
Reuters·07/11 14:30
NUCANA PLC - ADS RATIO CHANGE EFFECTIVE AUGUST 8, 2025
Barchart·07/11 09:30
NuCana Announces Plan to Implement ADS Ratio Change
Benzinga·07/10 09:47
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
TipRanks·07/09 17:27
NuCana Faces Delisting Threat as ADS Price Falls Below Nasdaq Requirements
Benzinga·07/09 17:06
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga·06/30 17:06
12 Health Care Stocks Moving In Monday's Intraday Session

Same Industry

Name/Symbol

Change%

Price

Nucana

NCNA

-8.86%

0.0391

Regeneron Pharmaceuticals

REGN

+2.46%

558.87

Entero Therapeutics

ENTO

-4.45%

0.4204

BIONTECH

BNTX

-0.15%

107.34

United Therapeutics Corp.

UTHR

+7.13%

294.28

Vertex Pharmaceuticals Inc

VRTX

+1.15%

462.13

Siga Technologie

SIGA

-2.27%

6.46

Moderna

MRNA

-6.61%

27.61

Charles Riv Labs Intl Inc

CRL

-1.61%

166.91

Medpace Holdings

MEDP

-0.96%

423.09

Talphera Inc

TLPH

-3.73%

0.4024

ICON PLC

ICLR

-1.63%

166.44

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

-1.83%

182.45

MOLECULAR PARTNERS AG

MOLN

-4.59%

3.53

Arcturus Therape

ARCT

+0.74%

12.30

Gilead Sciences Inc

GILD

+0.79%

113.18

PRA Health

PRAH

165.21

Incyte Corp

INCY

+0.93%

75.59

Aptevo Therapeutics Inc

APVO

-3.94%

2.68

Biospecifics

BSTC

+0.15%

88.53

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English